Search results for "Cystic"

showing 10 items of 461 documents

Inositols in the ovaries: activities and potential therapeutic applications.

2022

Introduction: Myo-inositol (MI) and D-chiro-inositol (DCI) play a key role in ovarian physiology, as they are second messengers of insulin and gonadotropins. Ex-vivo and in-vitro experiments demonstrate that both isomers are deeply involved in steroid biosynthesis, and that reduced MI-to-DCI ratios are associated with pathological imbalance of sex hormones. Areas covered: This expert opinion provides an overview of the physiological distribution of MI and DCI in the ovarian tissues, and a thorough insight of their involvement into ovarian steroidogenesis. Insulin resistance and compensatory hyperinsulinemia dramatically reduce the MI-to-DCI ratio in the ovaries, leading to gynecological dis…

PharmacologyOvarian SteroidogenesiGeneral MedicineToxicologySettore MED/40 - Ginecologia E Ostetriciad-chiro-inositol.EpimeraseSettore BIO/13 - Biologia ApplicataMyo-inositolSettore BIO/14 - FarmacologiaHumansInsulinFemaleInsulin ResistanceGenital Diseases FemaleInositolPolycystic Ovary SyndromeExpert opinion on drug metabolismtoxicology
researchProduct

PEGYLATED POLYASPARTAMIDE–POLYLACTIDE BASED NANOPARTICLES PENETRATING CYSTIC FIBROSIS ARTIFICIAL MUCUS

2016

Here, the preparation of mucus-penetrating nanoparticles for pulmonary administration of ibuprofen in patients with cystic fibrosis is described. A fluorescent derivative of α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide is synthesized by derivatization with rhodamine, polylactide, and poly(ethylene glycol), to obtain polyaspartamide− polylactide derivatives with different degrees of pegylation. Starting from these copolymers, fluorescent nanoparticles with different poly(ethylene glycol) content, empty and loaded with ibuprofen, showed spherical shape, colloidal size, slightly negative ζ potential, and biocompatibility toward human bronchial epithelial cells. The high surface poly(ethylene gly…

Polymers and PlasticsBiocompatibilityPolyestersαL-aspartamideNanoparticleBioengineeringIbuprofen02 engineering and technologyRespiratory Mucosa010402 general chemistry01 natural sciencesCell LinePolyethylene GlycolsBiomaterialsRhodaminecystic fibrosischemistry.chemical_compoundpolymeric nanoparticles cystic fibrosis αβ-poly(N-2-hydroxyethyl)-DL-aspartamideMaterials ChemistryCopolymerOrganic chemistryHumansDerivatizationβ-poly(N-2-hydroxyethyl)-Dpolymeric nanoparticles; cystic fibrosis; α; β-poly(N-2-hydroxyethyl)-D; L-aspartamide021001 nanoscience & nanotechnologyMucus0104 chemical sciencesMucuspolymeric nanoparticleschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPEGylationNanoparticles0210 nano-technologyPeptidesEthylene glycolNuclear chemistry
researchProduct

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

2006

Abstract Objective: The Androgen Excess Society (AES) charged a task force to review all available data and recommend an evidence-based definition for polycystic ovary syndrome (PCOS), whether already in use or not, to guide clinical diagnosis and future research. Participants: Participants included expert investigators in the field. Evidence: Based on a systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, we tried to identify studies evaluating the epidemiology or phenotypic aspects of PCOS. Consensus Process: The task force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and crit…

Position statementmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismBiochemistry (medical)Clinical BiochemistryHyperandrogenismMEDLINEGuidelinemedicine.diseaseAndrogen ExcessBiochemistryPolycystic ovaryEndocrinologyEndocrinologyInternal medicineEpidemiologyMedicinebusinessMedical literatureThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Immunohistochemical expression of glucose transporter 1 in keratin-producing odontogenic cysts

2016

Background: Keratin-producing odontogenic cysts (KPOCs) are a group of cystic lesions that are often aggressive, with high rates of recurrence and multifocality. KPOCs included orthokeratinised odontogenic cyst (OOC) and parakeratotic odontogenic cysts, which are now considered true tumours denominated keratocystic odontogenic tumours (KCOTs). GLUT1 is a protein transporter that is involved in the active uptake of glucose across cell membranes and that is overexpressed in tumours in close correlation with the proliferation rate and positron emission tomography (PET) imaging results. Methods: A series of 58 keratin-producing odontogenic cysts was evaluated histologically and immunohistochemi…

Positron emission tomographyPathologymedicine.medical_specialtyKeratocystic odontogenic tumourOdontogenic TumorsOdontologia03 medical and health sciences0302 clinical medicineKeratocystic odontogenic tumourGlucose transporter proteinKeratinmedicineHumansCàncerGeneral Dentistrychemistry.chemical_classificationGlucose Transporter Type 1medicine.diagnostic_testbiologyDentistry(all)business.industryKeratin-producing odontogenic cystGlucose transporterCancerEpithelial Cells030206 dentistrymedicine.diseasePatologiaImmunohistochemistryOrthokeratinised odontogenic cystchemistryPositron emission tomography030220 oncology & carcinogenesisOdontogenic Cystsbiology.proteinKeratinsImmunohistochemistryGLUT1businessGlucose Transporter Type 1Research ArticleBMC Oral Health
researchProduct

An overview on chemical structures as ΔF508-CFTR correctors

2019

Deletion of phenylalanine at position 508 (F508del) in the CFTR protein, is the most common mutation causing cystic fibrosis (CF). F508del causes misfolding and rapid degradation of CFTR protein a defect that can be targeted with pharmacological agents termed “correctors”. Correctors belong to various chemical classes but are generally small molecules based on nitrogen sulfur or oxygen heterocycles. The mechanism of action of correctors is generally unknown but there is experimental evidence that some of them can directly act on mutant CFTR improving folding and stability. Here we overview the characteristics of the various F508del correctors described so far to obtain indications on key ch…

Protein FoldingCystic FibrosisCFTR correctorMutantCystic Fibrosis Transmembrane Conductance RegulatorPyrimidinonesmedicine.disease_cause01 natural sciencesF508del-CFTR03 medical and health sciencesMutant proteinDrug DiscoverymedicineAnimalsHumansCFTR030304 developmental biologyPharmacology0303 health sciencesMutationCFTR correctorsbiology010405 organic chemistryChemistryOrganic ChemistryCFTR; CFTR correctors; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; F508del-CFTR; Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mutation; Protein Folding; Pyrimidinones; ThiazolesGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaSmall moleculeCystic fibrosis transmembrane conductance regulator0104 chemical sciencesCell biologyThiazolesMechanism of actionCystic fibrosiMutationbiology.proteinmedicine.symptomProtein Aδf508 cftrEuropean Journal of Medicinal Chemistry
researchProduct

Polyanion–tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

2016

Aim: Efficacy of antibiotics in cystic fibrosis (CF) is compromised by the poor penetration through mucus barrier. This work proposes a new ‘nano-into-micro’ approach, used to obtain a combinatorial effect: achieve a sustained delivery of tobramycin and overcome mucus barrier. Methods: Mannitol microparticles (MPs) were loaded with a tobramycin polymeric nanocomplex and characterized in presence of CF artificial mucus. Results & discussion: MPs are able to alter the rheological properties of CF artificial mucus, enhancing drug penetration into it and allowing a prolonged drug release. MPs resulted to be effective in Pseudomonas aeruginosa infections if compared with free tobramycin. Co…

Pseudomonas aeruginosa infectionCystic FibrosisPolymersmedicine.drug_classAntibioticsBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyDevelopmentBiologySettore BIO/19 - Microbiologia Generalenano into micro strategyCystic fibrosisCell LineNanocompositesMicrobiology03 medical and health sciences0302 clinical medicineAntibiotic resistancePseudomonas aeruginosa InfectionsmedicineTobramycinHumansMannitolPseudomonas InfectionsGeneral Materials ScienceDrug CarriersEpithelial CellsPenetration (firestop)021001 nanoscience & nanotechnologymedicine.diseasePolyelectrolytesMucusAnti-Bacterial AgentsDrug LiberationMucusmicroparticle030228 respiratory systemSettore CHIM/09 - Farmaceutico Tecnologico Applicativocystic fibrosis artificial mucuPseudomonas aeruginosaTobramycinMannitol0210 nano-technologyαβ-poly(N-2-hydroxyethyl)-DL-aspartamidespray dryermedicine.drugNanomedicine
researchProduct

Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

2019

Abstract Sustained pulmonary delivery of tobramycin from microparticles composed of drug/polymer nanocomplexes offers several advantages against traditional delivery methods. Namely, in patients with cystic fibrosis, microparticle delivery can protect the tobramycin being delivered from strong mucoadhesive interactions, thus avoiding effects on its diffusion toward the infection site. Polymeric ion-pair complexes were obtained starting from two synthetic polyanions, through impregnation of their solid dissociated forms with tobramycin in aqueous solution. The structure of these polymeric systems was characterized, and their activities were examined against various biofilm-forming Pseudomona…

Pseudomonas aeruginosa infectionpseudomonas aeruginosa infectionsBiocompatibilityCystic FibrosisαPharmaceutical Science02 engineering and technologymedicine.disease_cause030226 pharmacology & pharmacyCystic fibrosisCell Line03 medical and health sciences0302 clinical medicineIon-pair complexmedicineTobramycinHumansPseudomonas InfectionsMicroparticleαβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)chemistry.chemical_classificationDrug CarriersAqueous solutionPseudomonas aeruginosaBiofilms; Cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; Pseudomonas aeruginosa infections; Tobramycin; α; β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)BiofilmBiofilmPolymerBiofilms; cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; pseudomonas aeruginosa infections; Tobramycin; αβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)021001 nanoscience & nanotechnologymedicine.diseaseAnti-Bacterial AgentsMucuschemistryBiofilmsPseudomonas aeruginosaBiophysicsTobramycinNanoparticlescystic fibrosis artificial mucus (CF-AM)0210 nano-technologyPeptidesmedicine.drug
researchProduct

A NEW MODEL OF CF DISEASE: NO F508, NO KINASE?

2008

Pulmonary and Respiratory Medicine0303 health sciencesKinasebusiness.industryDiseasemedicine.diseaseCystic fibrosis03 medical and health sciences0302 clinical medicine030228 respiratory systemPediatrics Perinatology and Child HealthmedicineCancer researchPediatrics Perinatology and Child Healthbusinessskin and connective tissue diseases030304 developmental biologyJournal of Cystic Fibrosis
researchProduct

Cardiorespiratory Fitness and Physical Activity following Lung Transplantation: A National Cohort Study

2020

<b><i>Background:</i></b> Low cardiorespiratory fitness and inactivity are common after lung transplantation (LTx). The causes of exercise intolerance are incompletely understood. <b><i>Objectives:</i></b> The aim of this study was to objectively assess cardiorespiratory fitness and physical activity, evaluate causes of exercise intolerance, and explore clinical factors associated with cardiorespiratory fitness after bilateral LTx (BLTx). <b><i>Materials and Methods:</i></b> Peak oxygen uptake (V<b>∙</b>O<sub>2peak</sub>) and exercise-limiting factors were evaluated by a treadmill cardiopulmonary…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyCystic Fibrosismedicine.medical_treatmentPhysical activityNational cohortCohort Studies03 medical and health sciencesHemoglobinsPulmonary Disease Chronic ObstructiveYoung Adult0302 clinical medicineOxygen ConsumptionForced Expiratory VolumemedicineLung transplantationHumans030212 general & internal medicineLicenseExerciseAgedExercise ToleranceCardiovascular Deconditioningbusiness.industryNorwayPulmonary Gas ExchangeCardiorespiratory fitnessCardiopulmonary exercise testingCreative commonsMiddle AgedVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850030228 respiratory systemCardiorespiratory FitnessFamily medicineExercise TestFemalebusinessLung Diseases InterstitialVDP::Samfunnsvitenskap: 200::Samfunnsvitenskapelige idrettsfag: 330Lung Transplantation
researchProduct

Coil embolisation for massive haemoptysis in cystic fibrosis.

2021

IntroductionMassive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients with CF and haemoptysis after BAE using coils.MethodsWe carried out a retrospective cohort study of 34 adult patients treated for massive haemoptysis with super selective bronchial artery coil embolisation (ssBACE) between January 2008 and February 2015. Embolisation protocol was restricted to the culprit vessel(s) and three lobes maximum. Demographic data, functional end-expiratory volume in 1 s in % predicted (FEV1% pred.) and bod…

Pulmonary and Respiratory MedicineAdultmassive haemoptysismedicine.medical_specialtyHemoptysisCystic FibrosisMedizinBronchial ArteriesCulpritCystic fibrosisDiseases of the respiratory systemmedicine.arterymedicineHumansIn patient22181506Coil embolizationRetrospective StudiesRC705-779business.industryRRetrospective cohort studymedicine.diseaseEmbolization TherapeuticSurgeryMedicineSputummedicine.symptomBronchial arterybusinessBody mass indexBMJ open respiratory research
researchProduct